Related references
Note: Only part of the references are listed.From fixed activities to personalized treatments in radionuclide therapy: lost in translation?
G. D. Flux et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Dose Mapping After Endoradiotherapy with Lu-177-DOTATATE/DOTATOC by a Single Measurement After 4 Days
Heribert Haenscheid et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Peptide receptor radionuclide therapy with Lu-177-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival
Anastassia Loeser et al.
NUCLEAR MEDICINE COMMUNICATIONS (2018)
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
Anna Sundlov et al.
EJNMMI PHYSICS (2018)
Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (Lutate') therapy
Kathy P. Willowson et al.
EJNMMI PHYSICS (2018)
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
Alexandre Chicheportiche et al.
EJNMMI PHYSICS (2018)
Predictive power of the post-treatment scans after the initial or first two courses of [Lu-177]-DOTA-TATE
Alexandre Chicheportiche et al.
EJNMMI PHYSICS (2018)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course
Hendrik Bergsma et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative Lu-177 SPECT Applied for Dosimetry of Radiopharmaceutical Therapy
Michael Ljungberg et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment
Jorma Heikkonen et al.
ACTA ONCOLOGICA (2016)
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
Hendrik Bergsma et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours
Mattias Sandstrom et al.
EJNMMI PHYSICS (2015)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy
Ulrike Garske et al.
ACTA ONCOLOGICA (2012)
Lutetium-labelled peptides for therapy of neuroendocrine tumours
B. L. R. Kam et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Mattias Sandstrom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
USE OF NORMAL TISSUE COMPLICATION PROBABILITY MODELS IN THE CLINIC
Lawrence B. Marks et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Flavio Forrer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry-Standardization of Nomenclature
Wesley E. Bolch et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
